
Global Cancer Biomarkers Market Report and Forecast 2024-2032
Description
Global Cancer Biomarkers Market Report and Forecast 2024-2032
Global Cancer Biomarkers Market Report and Forecast 2024-2032
The global cancer biomarkers market size was valued at USD 15.8 billion in 2023. The market is expected to grow at a CAGR of 14.30% and is likely to reach USD 52.4 billion by 2032. It is driven by growing emphasis on early detection and personalized medicine across the globe.
Global Cancer Biomarkers Market Analysis
The global cancer biomarkers market is a rapidly evolving sector, characterized by significant growth driven by advancements in cancer detection, diagnosis, and therapeutic monitoring. As critical indicators of the biological status of cancer, biomarkers play an indispensable role in improving the efficacy of cancer treatment and patient outcomes. This analysis aims to provide a comprehensive overview of the current state of the global cancer biomarkers market, including market drivers, challenges, key players, and future trends.
Global Cancer Biomarkers Market Drivers
The primary factor propelling the growth of the cancer biomarkers market is the increasing prevalence of various cancers worldwide. This surge is accompanied by a growing emphasis on early detection and personalized medicine, which rely heavily on biomarkers for accurate diagnosis and treatment customization. Additionally, technological advancements in genomics and proteomics have significantly enhanced the discovery and validation of novel biomarkers, further stimulating market expansion. Public and private investments in cancer research, coupled with favorable government initiatives, also contribute to the market's growth.
Market Challenges
Despite the promising growth, the cancer biomarkers market faces several challenges. High costs associated with biomarker development and validation, coupled with stringent regulatory requirements, pose significant hurdles. Moreover, the complexity of cancer biology often leads to difficulties in identifying specific and sensitive biomarkers, impacting the effectiveness of cancer diagnosis and treatment. Issues related to reimbursement policies and the ethical concerns surrounding genetic testing also impede market progression.
Global Cancer Biomarkers Market Outlook
Looking ahead, the cancer biomarkers market is expected to witness continued growth, driven by ongoing research and technological innovations. The integration of artificial intelligence and machine learning in biomarker discovery and validation is anticipated to revolutionize the market, enabling the identification of novel biomarkers with enhanced accuracy and speed. Additionally, the increasing adoption of liquid biopsies as a non-invasive method for cancer detection and monitoring is likely to boost market growth further.
Global Cancer Biomarkers Market Trends
The global cancer biomarkers market is witnessing several trends driven by the increasing prevalence of cancer, advancements in technology, and the growing emphasis on personalized medicine. Here are some of the key trends that were shaping the market:
- Advancements in Genomics and Proteomics
- Increased Adoption of Liquid Biopsies
- Growth of Personalized Medicine
- Rising Investment in Cancer Research and Biomarker Discovery
- Integration of Artificial Intelligence and Machine Learning
- Collaborations and Partnerships
- Regulatory Support and Approval
- Emerging Markets
Global Cancer Biomarkers Market Segmentation
Market Breakup by Type
- Protein Biomarkers
- Genetic Biomarkers
- Others
Market Breakup by Cancer Type
- Lung cancer
- Breast cancer
- Leukemia cancer
- Melanoma
- Colorectal cancer
- Prostate cancer
- Others
Market Breakup by Applications
- Prognostics
- Diagnostics
- Research and development
- Others
Market Breakup by Profiling Technology
- Omics
- Imaging
- Immunoassay
- Bioinformatics
- Others
Market Breakup by End User
- Pharmaceuticals and Biotechnology Companies
- Diagnostics and Research Laboratories
- Hospitals
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Cancer Biomarkers Market Competitive Landscape
The competitive landscape of the global cancer biomarkers market is characterized by the presence of several key players, each contributing to advancements in cancer diagnostics and personalized medicine. Illumina, Inc., F. Hoffmann-La Roche Ltd,Bio-Rad Laboratories, Inc., Qiagen N.V., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Siemens Healthcare Private Limited, PerkinElmer Inc., Bio-Techne, Hologic, Inc., Quest Diagnostics Clinical Laboratories, Inc., alongside Charles River Laboratories, are some of the leading market players. Together, these entities form a dynamic and innovative ecosystem driving progress in cancer biomarker development and application.
Key Questions Answered in the Report
- What is the current and future performance of the global cancer biomarkers market?
- What are the factors that influence the growth, decline, and potential of the global cancer biomarkers market?
- What are the key factors driving the growth of the global cancer biomarkers market?
- What are the main challenges hindering the progression of the cancer biomarkers market?
- What future trends are expected to drive the growth of the cancer biomarkers market?
- How is the global cancer biomarkers market segmented, and what are the growth prospects for each segment?
- What is the market segmentation by cancer type, and which segments are leading in market share?
- How is the global cancer biomarkers market segmented based on applications, and which segments are dominating the market?
- How is the market organized in terms of competition?
- What are the main players/companies in the market?
- The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global cancer biomarkers market from 2017-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the global cancer biomarkers market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the global cancer biomarkers industry and its attractiveness.
- The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Cancer Biomarkers Market Overview
- 3.1 Global Cancer Biomarkers Market Historical Value (2017-2023)
- 3.2 Global Cancer Biomarkers Market Forecast Value (2024-2032)
- 4 Global Cancer Biomarkers Market Landscape*
- 4.1 Global Cancer Biomarkers: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Cancer Biomarkers: Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Technology
- 4.2.3 Analysis by Applications
- 5 Global Cancer Biomarkers Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Cancer Biomarkers Market Segmentation (2017-2032)
- 6.1 Global Cancer Biomarkers Market (2017-2032) by Type
- 6.1.1 Market Overview
- 6.1.2 Protein Biomarkers
- 6.1.3 Genetic Biomarkers
- 6.1.4 Others
- 6.2 Global Cancer Biomarkers Market (2017-2032) by Cancer Type
- 6.2.1 Market Overview
- 6.2.2 Lung Cancer
- 6.2.3 Breast Cancer
- 6.2.4 Leukemia
- 6.2.5 Melanoma
- 6.2.6 Colorectal Cancer
- 6.2.7 Prostate Cancer
- 6.2.8 Others
- 6.3 Global Cancer Biomarkers Market (2017-2032) by Applications
- 6.3.1 Market Overview
- 6.3.2 Prognostics
- 6.3.3 Diagnostics
- 6.3.4 Research and Development
- 6.3.5 Others
- 6.4 Global Cancer Biomarkers Market (2017-2032) by Profiling Technology
- 6.4.1 Market Overview
- 6.4.2 Omics
- 6.4.3 Imaging
- 6.4.4 Immunoassay
- 6.4.5 Bioinformatics
- 6.4.6 Others
- 6.5 Global Cancer Biomarkers Market (2017-2032) by End-User
- 6.5.1 Market Overview
- 6.5.2 Pharmaceuticals and Biotechnology Companies
- 6.5.3 Diagnostics and Research Laboratories
- 6.5.4 Hospitals
- 6.5.5 Others
- 6.6 Global Cancer Biomarkers Market (2017-2032) by Region
- 6.6.1 Market Overview
- 6.6.2 North America
- 6.6.3 Europe
- 6.6.4 Asia Pacific
- 6.6.5 Latin America
- 6.6.6 Middle East and Africa
- 7 North America Cancer Biomarkers Market (2017-2032)
- 7.1 North America Cancer Biomarkers Market (2017-2032) by Type
- 7.1.1 Market Overview
- 7.1.2 Protein Biomarkers
- 7.1.3 Genetic Biomarkers
- 7.1.4 Others
- 7.2 North America Cancer Biomarkers Market (2017-2032) by Cancer Type
- 7.2.1 Market Overview
- 7.2.2 Lung
- 7.2.3 Breast
- 7.2.4 Leukemia
- 7.2.5 Melanoma
- 7.2.6 Colorectal
- 7.2.7 Prostate
- 7.2.8 Others
- 7.3 North America Cancer Biomarkers Market (2017-2032) by Country
- 7.3.1 United States of America
- 7.3.2 Canada
- 8 Europe Cancer Biomarkers Market (2017-2032)
- 8.1 Europe Cancer Biomarkers Market (2017-2032) by Type
- 8.1.1 Market Overview
- 8.1.2 Protein Biomarkers
- 8.1.3 Genetic Biomarkers
- 8.1.4 Others
- 8.2 Europe Cancer Biomarkers Market (2017-2032) by Cancer Type
- 8.2.1 Market Overview
- 8.2.2 Lung cancer
- 8.2.3 Breast cancer
- 8.2.4 Leukemia cancer
- 8.2.5 Melanoma
- 8.2.6 Colorectal
- 8.2.7 Prostate
- 8.2.8 Others
- 8.3 Europe Cancer Biomarkers Market (2017-2032) by Country
- 8.3.1 United Kingdom
- 8.3.2 Germany
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Others
- 9 Asia Pacific Cancer Biomarkers Market (2017-2032)
- 9.1 Asia Pacific Cancer Biomarkers Market (2017-2032) by Type
- 9.1.1 Market Overview
- 9.1.2 Protein Biomarkers
- 9.1.3 Genetic Biomarkers
- 9.1.4 Others
- 9.2 Asia Pacific Cancer Biomarkers Market (2017-2032) by Cancer Type
- 9.2.1 Market Overview
- 9.2.2 Lung cancer
- 9.2.3 Breast cancer
- 9.2.4 Leukemia cancer
- 9.2.5 Melanoma
- 9.2.6 Colorectal
- 9.2.7 Prostate
- 9.2.8 Others
- 9.3 Asia Pacific Cancer Biomarkers Market (2017-2032) by Country
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 ASEAN
- 9.3.5 Australia
- 9.3.6 Others
- 10 Latin America Cancer Biomarkers Market (2017-2032)
- 10.1 Latin America Cancer Biomarkers Market (2017-2032) by Type
- 10.1.1 Market Overview
- 10.1.2 Protein Biomarkers
- 10.1.3 Genetic Biomarkers
- 10.1.4 Others
- 10.2 Latin America Cancer Biomarkers Market (2017-2032) by Cancer Type
- 10.2.1 Market Overview
- 10.2.2 Lung cancer
- 10.2.3 Breast cancer
- 10.2.4 Leukemia cancer
- 10.2.5 Melanoma
- 10.2.6 Colorectal
- 10.2.7 Prostate
- 10.2.8 Others
- 10.3 Latin America Cancer Biomarkers Market (2017-2032) by Country
- 10.3.1 Brazil
- 10.3.2 Argentina
- 10.3.3 Mexico
- 10.3.4 Others
- 11 Middle East and Africa Cancer Biomarkers Market (2017-2032)
- 11.1 Middle East and Africa Cancer Biomarkers Market (2017-2032) by Type
- 11.1.1 Market Overview
- 11.1.2 Protein Biomarkers
- 11.1.3 Genetic Biomarkers
- 11.1.4 Others
- 11.2 Middle East and Africa Cancer Biomarkers Market (2017-2032) by Cancer Type
- 11.2.1 Market Overview
- 11.2.2 Lung cancer
- 11.2.3 Breast cancer
- 11.2.4 Leukemia cancer
- 11.2.5 Melanoma
- 11.2.6 Colorectal
- 11.2.7 Prostate
- 11.2.8 Others
- 11.3 Middle East and Africa Cancer Biomarkers Market (2017-2032) by Country
- 11.3.1 Saudi Arabia
- 11.3.2 United Arab Emirates
- 11.3.3 Nigeria
- 11.3.4 South Africa
- 11.3.5 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by Year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Illumina, Inc.
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 F. Hoffmann-La Roche Ltd.
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Bio-Rad Laboratories, Inc.
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Qiagen N.V.
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Thermo Fisher Scientific Inc.
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Myriad Genetics, Inc.
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Siemens Healthcare Private Limited
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 PerkinElmer Inc.
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Bio-Techne
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 Hologic, Inc.
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 Quest Diagnostics Clinical Laboratories, Inc.
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 Charles River Laboratories
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- List not exhaustive
- 18 Global Cancer Biomarkers Market – Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.